Skip to content

A New Monitor to Measure Dermal Blood Flow in Critically Ill Patients: a Preliminary Study

A New Monitor to Measure Dermal Blood Flow in Critically Ill Patients: a Preliminary Study

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01794468
Acronym
MDBF-CIP
Enrollment
11
Registered
2013-02-18
Start date
2003-06-30
Completion date
2005-07-31
Last updated
2013-02-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Critically Ill Patients, Positive-Pressure Respiration, Intrinsic

Keywords

Dermal blood flow, critically ill

Brief summary

Background: Conditions of reduced perfusion are characterized by redistribution of blood flow away from the skin to more vital organs. Study Objectives: To assess the efficacy of a non-invasive, dermal blood flow (DBF) monitor in detecting changes in perfusion in critically ill patients. Preliminary Study Study Population: critically ill patients in a general ICU

Detailed description

DBF, finger plethysmography and invasive mean arterial pressure (MAP) were recorded over an 8-hour period. DBF was measured using the I.S. MedTech DBF monitor, based on the hot-wire principle of thermal balance of a heater cooled by a moving medium, via a skin probe placed on the anterior chest wall. Sensitivity was evaluated by visual inspection during active states, either induced, e.g. fluid administration, or spontaneous, e.g. altered hemodynamics. Specificity was evaluated during stable states (minimal fluctuations of MAP and no active interventions applied or required). Data are expressed in terms of standard deviation (SD) and of the difference (SDD) between the MAP and each of the tested methods.

Interventions

OTHERDermal blood flow measurements

Dermal blood flow was measured with the Dermal Blood Flow (DBF) monitor (I.S. MedTech, Israel), which consists of a skin probe and a measuring and control feedback unit.

Sponsors

Rabin Medical Center
Lead SponsorOTHER

Study design

Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
BASIC_SCIENCE
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* All patients were ventilated and sedated during an 8-hour period of measurement

Exclusion criteria

* Age \< 18 years old

Design outcomes

Primary

MeasureTime frameDescription
Dermal blood flow measurementsover an 8-hour periodDBF monitor - non-invasive method for detecting changes in perfusion in critically ill patients.

Countries

Israel

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026